BR112018012934A2 - reguladores cftr e métodos de uso dos mesmos - Google Patents

reguladores cftr e métodos de uso dos mesmos

Info

Publication number
BR112018012934A2
BR112018012934A2 BR112018012934A BR112018012934A BR112018012934A2 BR 112018012934 A2 BR112018012934 A2 BR 112018012934A2 BR 112018012934 A BR112018012934 A BR 112018012934A BR 112018012934 A BR112018012934 A BR 112018012934A BR 112018012934 A2 BR112018012934 A2 BR 112018012934A2
Authority
BR
Brazil
Prior art keywords
methods
cftr
regulators
cftr regulators
disorders
Prior art date
Application number
BR112018012934A
Other languages
English (en)
Other versions
BR112018012934B1 (pt
Inventor
Verkman Alan
H Levin Marc
J Kurth Mark
Cil Onur
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112018012934A2 publication Critical patent/BR112018012934A2/pt
Publication of BR112018012934B1 publication Critical patent/BR112018012934B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

são fornecidos no presente documento compostos que ativam cftr e métodos para tratar constipação, transtornos de olho seco e outras doenças e transtornos.
BR112018012934-8A 2015-12-24 2016-12-23 Reguladores cftr e métodos de uso dos mesmos BR112018012934B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562387579P 2015-12-24 2015-12-24
US62/387,579 2015-12-24
US201662376808P 2016-08-18 2016-08-18
US62/376,808 2016-08-18
PCT/US2016/068566 WO2017112950A1 (en) 2015-12-24 2016-12-23 Cftr regulators and methods of use thereof

Publications (2)

Publication Number Publication Date
BR112018012934A2 true BR112018012934A2 (pt) 2018-12-11
BR112018012934B1 BR112018012934B1 (pt) 2023-11-07

Family

ID=59091221

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012934-8A BR112018012934B1 (pt) 2015-12-24 2016-12-23 Reguladores cftr e métodos de uso dos mesmos

Country Status (18)

Country Link
US (2) US11084795B2 (pt)
EP (2) EP3394046B1 (pt)
JP (2) JP6938509B2 (pt)
KR (1) KR20180101416A (pt)
CN (1) CN108699040B (pt)
AU (1) AU2016377785B2 (pt)
BR (1) BR112018012934B1 (pt)
CA (1) CA3009534A1 (pt)
CL (1) CL2018001716A1 (pt)
CO (1) CO2018007236A2 (pt)
DK (1) DK3394046T3 (pt)
ES (1) ES2913051T3 (pt)
IL (1) IL260212B (pt)
PL (1) PL3394046T3 (pt)
PT (1) PT3394046T (pt)
RU (1) RU2730855C2 (pt)
WO (1) WO2017112950A1 (pt)
ZA (1) ZA201804229B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180102590A (ko) 2015-12-24 2018-09-17 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 사용방법
KR20180101416A (ko) * 2015-12-24 2018-09-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 이용 방법
KR20200044873A (ko) * 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA794209B (en) * 1978-08-15 1980-07-30 Fisons Ltd Pharmaceutically active heterocyclic compounds
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
US4181724A (en) 1978-09-11 1980-01-01 The Upjohn Company Quinoxalinone compounds useful for expanding the lumina or air passages in mammals
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
FR2653430B1 (fr) 1989-10-23 1991-12-20 Pf Medicament Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique.
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
AU5433594A (en) 1992-11-19 1994-06-08 Dainippon Pharmaceutical Co. Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU1917999A (en) 1998-03-31 1999-10-18 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
BRPI0811145A2 (pt) 2007-05-22 2014-12-23 Astellas Pharma Inc Composto tetraidroisoquinolina 1-substituído
EA021904B1 (ru) 2008-03-05 2015-09-30 Мерк Патент Гмбх Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета
NZ592687A (en) * 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
BR112015014433A2 (pt) * 2012-12-19 2017-07-11 Novartis Ag compostos tricíclicos
WO2015168079A1 (en) * 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
KR20180101416A (ko) * 2015-12-24 2018-09-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 이용 방법

Also Published As

Publication number Publication date
US20210347742A1 (en) 2021-11-11
IL260212A (en) 2018-07-31
BR112018012934B1 (pt) 2023-11-07
US11084795B2 (en) 2021-08-10
EP3394046B1 (en) 2022-03-09
JP7297828B2 (ja) 2023-06-26
ZA201804229B (en) 2021-10-27
AU2016377785A1 (en) 2018-07-12
JP2018538352A (ja) 2018-12-27
RU2730855C2 (ru) 2020-08-26
AU2016377785A2 (en) 2018-08-23
KR20180101416A (ko) 2018-09-12
IL260212B (en) 2021-08-31
AU2016377785B2 (en) 2021-07-01
JP6938509B2 (ja) 2021-09-22
EP3394046A4 (en) 2019-06-19
EP3394046A1 (en) 2018-10-31
CL2018001716A1 (es) 2018-10-26
JP2021185186A (ja) 2021-12-09
CN108699040B (zh) 2021-08-10
EP4071140A1 (en) 2022-10-12
CN108699040A (zh) 2018-10-23
DK3394046T3 (da) 2022-04-04
CA3009534A1 (en) 2017-06-29
PT3394046T (pt) 2022-04-05
PL3394046T3 (pl) 2022-06-13
WO2017112950A1 (en) 2017-06-29
US20190031622A1 (en) 2019-01-31
RU2018126957A3 (pt) 2020-02-28
RU2018126957A (ru) 2020-01-27
ES2913051T3 (es) 2022-05-31
CO2018007236A2 (es) 2018-07-19

Similar Documents

Publication Publication Date Title
CL2017003103A1 (es) Compuestos de heteroarilo para la inhibición de cinasa
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
BR112018070133A2 (pt) dispersão, uso desta e método para a inativação fotodinâmica de micro-organismos
CO2017010890A2 (es) Derivados de maitansinoide, conjugados del mismo, y metodos de uso
BR112017006664A2 (pt) terapias de combinação
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
BR112015023760A2 (pt) compostos e composições terapêuticas
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112018012927A2 (pt) reguladores cftr e métodos de uso dos mesmos
CL2017001046A1 (es) Inhibidoes del bromodominio
BR112018011709A2 (pt) inibidores bicíclicos de pad4
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso
UY36716A (es) Moduladores de receptores nucleares

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 403/04 , C07D 405/04 , C07D 401/04

Ipc: C07D 403/04 (2006.01), C07D 405/04 (2006.01), C07D

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2016, OBSERVADAS AS CONDICOES LEGAIS